ClinicalTrials.gg
CompletedNCT03302104Updated Oct 4, 2017

Diet Quality and LTL in NHANES

An observational study in Telomere Length, Mean Leukocyte and Diet Habit, sponsored by University of California, San Francisco. Completed. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-10-04.

Sponsored by University of California, San Francisco · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
4,758
Ages
20 Years to 65 Years
Sex
All
01

Study summary

In our study, we used data from 4,758 healthy adults from the 1999-2002 National Health and Nutrition Examination Surveys to examine the associations between evidence-based diet quality indices and leukocyte telomere length. Our study assessed the four most widely recognized and commonly used diet quality indices in nutritional epidemiology: the USDA-developed Healthy Eating Index-2010, the Alternate Healthy Eating Index-2010, the Mediterranean Diet Score, and the DASH diet score. Analyses were adjusted for sociodemographic and health variables known to influence dietary intake and cellular aging.

02

Conditions studied

  • Telomere Length, Mean Leukocyte
  • Diet Habit

Browse trials for

03

In context

Feeding Behavior

985 studies on the registry are indexed under Feeding Behavior; 178 are open to participants now.

This study's enrollment of 4,758 is above the median of 183 across 270 observational studies indexed under Feeding Behavior.

Browse Feeding Behavior studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

The study population was comprised of 4,758 healthy adults, aged 20 to 65 years, who had complete dietary and leukocyte telomere length (LTL) data measured in 1999-2002 National Health and Nutrition Examination Surveys (NHANES), without a prior diagnosis of major chronic disease (coronary heart disease, angina, myocardial infarction, stroke, diabetes, congestive heart failure, and cancer).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 20 to 65 years
  • No prior diagnosis of major chronic disease (coronary heart disease, angina, myocardial infarction, stroke, diabetes, congestive heart failure, and cancer)

Exclusion criteria

Exclusion Criteria:

  • Prior diagnosis of major chronic disease (coronary heart disease, angina, myocardial infarction, stroke, diabetes, congestive heart failure, and cancer)
  • Younger than age 20 or older than age 65
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
4,758 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Leukocyte telomere length

    Time frame: 1999-2002

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03302104
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
Jan 1, 1999
Primary completion
Dec 31, 2002
Completion
Dec 31, 2002
Last update
Oct 4, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion